We are live on
!
Find out more
OPPM
Opus Point Partners Management Portfolio holdings
AUM
$55.3M
1-Year Est. Return
7.48%
This Fund
S&P 500
This Quarter
Est. Return
+20.38%
1 Year Est. Return
-7.48%
3 Year Est. Return
+85.18%
5 Year Est. Return
+168.21%
10 Year Est. Return
–
AUM
$101M
AUM Growth
–
Cap. Flow
+$93.1M
Cap. Flow
% of AUM
92.16%
Top 10 Holdings %
Top 10 Hldgs %
37.84%
Holding
57
New
57
Increased
–
Reduced
–
Closed
–
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
ProShares Ultra NASDAQ Biotechnology
BIB
|
+$4.48M |
| 2 |
Incyte
INCY
|
+$3.98M |
| 3 |
BioMarin Pharmaceuticals
BMRN
|
+$3.64M |
| 4 |
State Street SPDR S&P Biotech ETF
XBI
|
+$3.56M |
| 5 |
CELG
Celgene Corp
CELG
|
+$3.48M |
Top Sells
No sells this quarter
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 70.4% |
| 2 | Miscellaneous | 29.6% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
ProShares Ultra NASDAQ Biotechnology
BIB
$105M
| $4.79M | 4.74% |
+76,368
| New | +$4.48M |
|
|
2
Incyte
INCY
$25.9B
| $4.45M | 4.4% |
+60,877
| New | +$3.98M |
|
|
3
BioMarin Pharmaceuticals
BMRN
$12.6B
| $3.95M | 3.91% |
+43,731
| New | +$3.64M |
|
|
4
State Street SPDR S&P Biotech ETF
XBI
$11.7B
| $3.88M | 3.84% |
+62,400
| New | +$3.56M |
|
|
CELG
5
DELISTED
Celgene Corp
CELG
| $3.7M | 3.66% |
+33,040
| New | +$3.48M |
|
6
Nektar Therapeutics
NKTR
$2.55B
| $3.68M | 3.64% |
+15,807
| New | +$3.38M |
|
7
Regeneron Pharmaceuticals
REGN
$83.2B
| $3.55M | 3.51% |
+8,650
| New | +$3.4M |
|
8
Vertex Pharmaceuticals
VRTX
$139B
| $3.46M | 3.42% |
+29,096
| New | +$3.28M |
|
9
Illumina
ILMN
$34.4B
| $3.4M | 3.36% |
+18,909
| New | +$3.33M |
|
|
ALXN
10
DELISTED
Alexion Pharmaceuticals
ALXN
| $3.39M | 3.36% |
+18,332
| New | +$3.4M |
|
|
CPHD
11
DELISTED
Cepheid Inc
CPHD
| $3.27M | 3.23% |
+60,386
| New | +$3.05M |
|
12
Biogen
BIIB
$32.7B
| $3.22M | 3.19% |
+9,486
| New | +$3.07M |
|
|
PCYC
13
DELISTED
PHARMACYCLICS INC
PCYC
| $3.15M | 3.11% |
+25,723
| New | +$3.29M |
|
|
MDVN
14
DELISTED
MEDIVATION, INC.
MDVN
| $3.13M | 3.09% |
+62,754
| New | +$3.26M |
|
15
Mettler-Toledo International
MTD
$28.2B
| $3.02M | 2.99% |
+10,000
| New | +$2.75M |
|
|
RCPT
16
DELISTED
RECEPTOS INC COM STK (DE)
RCPT
| $2.81M | 2.78% |
+22,971
| New | +$2.33M |
|
17
Ionis Pharmaceuticals
IONS
$10.4B
| $2.8M | 2.77% |
+45,418
| New | +$2.24M |
|
18
Amgen
AMGN
$236B
| $2.71M | 2.69% |
+17,046
| New | +$2.66M |
|
|
QGENF
19
DELISTED
QIAGEN NV
QGENF
| $2.67M | 2.65% |
+114,000
| New | +$2.67M |
|
|
SGEN
20
DELISTED
Seagen Inc. Common Stock
SGEN
| $2.64M | 2.61% |
+82,253
| New | +$2.87M |
|
21
Bio-Techne
TECH
$11.4B
| $2.58M | 2.55% |
+111,600
| New | +$2.55M |
|
22
United Therapeutics
UTHR
$22.6B
| $2.47M | 2.44% |
+19,054
| New | +$2.46M |
|
|
SLXP
23
DELISTED
SALIX PHARMACEUTICALS LTD DEL
SLXP
| $2.09M | 2.07% |
+18,187
| New | +$2.2M |
|
|
GEVA
24
DELISTED
SYNAGEVA BIOPHARMA CORP COM STK (DE)
GEVA
| $1.86M | 1.84% |
+20,002
| New | +$1.58M |
|
25
Alnylam Pharmaceuticals
ALNY
$31.7B
| $1.73M | 1.72% |
+17,875
| New | +$1.66M |
|
Similar funds
KIA
PGA
GX
SCG
TCMV
FCM
DP
SAM
Opus Point Partners Management's Q4 2014 Portfolio in Review
Q4 2014 is the first quarter with a 13F filing on record for Opus Point Partners Management, which disclosed 57 positions worth $101M. Its ten largest holdings account for 38% of the portfolio.
Its largest position is ProShares Ultra NASDAQ Biotechnology: 76,368 shares worth $4.79M.
By sector, the portfolio is most concentrated in Healthcare at 70% of assets, followed by Miscellaneous.
- Opus Point Partners Management's largest Q4 2014 buy was ProShares Ultra NASDAQ Biotechnology: 76,368 shares worth $4.79M.
- Opus Point Partners Management's ten largest holdings make up 38% of its $101M portfolio in Q4 2014.
- Opus Point Partners Management disclosed 57 positions in Q4 2014, its first 13F filing on record.
Based on Opus Point Partners Management's 13F filing for Q4 2014, filed 17 Feb 2015.